Peptide And Oligonucleotide CDMO Global Market Report 2024

The peptide and oligonucleotide CDMO market size has grown rapidly in recent years. It will grow from $1.93 billion in 2023 to $2.16 billion in 2024 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to a rise in demand for therapeutic agents, advancements in synthesis and manufacturing, trends in personalized medicine, regulatory guidelines, and increased focus on antiviral peptides and mRNA vaccines, highlighting the potential of oligonucleotides in vaccine development.

The peptide and oligonucleotide CDMO market size is expected to see rapid growth in the next few years. It will grow to $3.39 billion in 2028 at a compound annual growth rate (CAGR) of 12%. The growth in the forecast period can be attributed to the growing demand for personalized medicine, advancements in biotechnology, expanding applications, increasing outsourcing, and the growing burden of chronic diseases. Major trends expected in the forecast period include personalized therapies, technological advancements, challenges in quality control, global expansion, and increased collaboration among biopharmaceutical companies.

The peptide and oligonucleotide CDMO markets are poised for growth, driven by the increasing adoption of personalized medicine. Personalized medicine tailors healthcare decisions and treatments to individual characteristics such as genetics, lifestyle, and environment. This trend is fueled by advancements in genomic technologies, deeper insights into disease mechanisms at the molecular level, and the demand for more targeted and effective treatment options customized to patients' genetic profiles and medical histories. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) play a pivotal role in personalized medicine by producing customized therapeutic peptides and oligonucleotides to meet individual patient needs. For example, in February 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 16 new personalized treatments for rare disease patients, a notable increase from the previous year. Consequently, the rising adoption of personalized medicine is propelling the peptide and oligonucleotide CDMO market forward.

Key players in the peptide and oligonucleotide CDMO market are forging strategic partnerships to enrich their service offerings, enhance technological capabilities, and broaden market presence. Peptide development and production partnerships entail collaborative efforts between organizations to develop and manufacture peptide-based therapeutics. For instance, in May 2023, PolyPeptide Group AG teamed up with Numaferm GmbH for peptide development and production. This collaboration harnesses PolyPeptide's cGMP manufacturing capacities and market access alongside Numaferm's expertise in sustainable peptide manufacturing and biochemical production platforms. The aim is to jointly explore the development of suitable peptide candidates for more sustainable production of peptide-based APIs.

In May 2024, EUROAPI strengthened its foothold in the oligonucleotide CDMO market by acquiring BianoGMP, further enhancing its capacity in Frankfurt. BianoGMP, a Germany-based CDMO specializing in providing analytical services for oligonucleotides, augments EUROAPI's capabilities, positioning it for expanded growth and innovation in the oligonucleotide segment.

Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

North America was the largest region in the peptide and oligonucleotide CDMO market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the peptide and oligonucleotide cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A peptide and oligonucleotide CDMO (contract development and manufacturing organization) refers to a company that offers services for the development, manufacturing, and supply of peptides and oligonucleotide-based therapeutics. These organizations specialize in synthetic chemistry, process development, analytical testing, and cGMP manufacturing to support the production of peptides and oligonucleotides for various companies.

The main product types provided by peptide and oligonucleotide CDMOs are peptides and oligonucleotides. Peptides are short chains of amino acids, typically less than 50 amino acids in length, that play crucial roles in biological processes such as signaling and hormone regulation. These CDMOs offer services including contract development and contract manufacturing. Peptides and oligonucleotides find applications in therapeutics, research applications, diagnostics, and other fields, and are utilized by end-users such as biopharmaceutical companies, pharmaceutical companies, research institutes, academic and government organizations, among others.

The peptide and oligonucleotide CDMO market research report is one of a series of new reports that provides peptide and oligonucleotide CDMO market statistics, including the peptide and oligonucleotide CDMO industry global market size, regional shares, competitors with peptide and oligonucleotide CDMO market share, detailed peptide and oligonucleotide CDMO market segments, market trends, and opportunities, and any further data you may need to thrive in the peptide and oligonucleotide CDMO industry. These peptide and oligonucleotide CDMO market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The peptide and oligonucleotide CDMO market consists of revenues earned by entities by providing services such as analytical testing, oligonucleotide synthesis services, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The peptide and oligonucleotide CDMO market also includes sales of custom peptides and custom oligonucleotides. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.